Abstract. Because of the difficulty in identifying botulinum toxin in cattle, it is hypothesized that cattle are sensitive to levels of toxin below the detection limits of current diagnostic techniques (the mouse protection bioassay and the immunostick enzyme-linked immunosorbent assay [ELISA] for type C botulinum toxin). Using an up-down method for toxicologic testing, the median toxic dose (MTD 50 ) for cattle was determined. Four lactating Holstein cows were dosed at 0.125 or 0.25 ng/kg with Clostridium botulinum type C toxin and failed to develop clinical signs of botulism during the 7-day observation period. Three cows given 0.50 ng/kg of toxin developed clinical signs of botulism. From these results, the MTD 50 was calculated at 0.388 ng/kg (3.88 mouse lethal doses/kg) using the trim-logit method. These results suggest that cattle are 12.88 times more sensitive to type C botulinum toxin than a mouse on a per kilogram weight basis. The mouse protection bioassay and the immunostick ELISA for type C botulinum toxin failed to identify the presence of the toxin in the serum, blood, and milk samples taken from all 7 animals.
Botulism is caused by a neurotoxin produced by Clostridium botulinum. The disease affects most mammals and birds. Eight different botulinum toxins have been identified on the basis of immunological characteristics and are designated as types A, B, C 1 , C 2 , D, E, F, and G. Type A, B, C, and occasionally D botulinum toxins have affected cattle in North America. In California, several outbreaks of botulism in cattle have occurred during the past few years and resulted in catastrophic losses. In one case, 427 of 444 adult lactating Holstein dairy cows died after the ingestion of feed inadvertently mixed with a dead cat that was contaminated with botulinum type C toxin. 4 Type C botulism usually occurs with the accidental feeding of carrion (bird, cat, or dog carcasses) in the ration to cattle. Clostridium botulinum spores vegetate in the proteinrich anaerobic environment of the carcass after death, producing the potent neurotoxin. In the past, feeding of poultry litter, especially litter containing chicken carcasses, has been associated with outbreaks of botulism in beef cattle. 1, 6, 8, 10, 11 Exposure of the cattle to a ration contaminated with decomposing carcasses containing botulinum toxin results in absorption of the toxin from the gastrointestinal tract and clinical signs of botulism. Laboratory diagnosis of botulism is at- tempted by inoculating mice with extracts of serum, liver, and gastrointestinal contents. This approach has been shown to be successful for the diagnosis of botulism in avian species but has had more limited success with samples collected from cattle and horses. In the case reported above, attempts to detect the toxin in blood and liver from affected cattle using the mouse protection bioassay and the immunostick enzymelinked immunosorbent assay (ELISA) specific for type C toxin failed. However, toxin was successfully identified in tissue fragments of a cat carcass that had contaminated the total mixed ration, as well as in 2 samples from the rumen content of the affected cows. Botulism is usually a clinical diagnosis. Demonstration of preformed toxin in serum, feed material, or rumen content by use of the mouse protection bioassay is the major definitive test. Because of its extreme toxicity at low doses, botulinum toxin is frequently not detected in animal samples, and the diagnosis of botulism depends on finding the source of the botulinum toxin. The lack of positive results from the serum or liver of cattle that have died of botulism has led to the hypothesis that cattle may be much more sensitive to botulinum toxin than mice. In addition, the sensitivity of the type C immunostick ELISA may also not be high enough to successfully detect botulinum toxin in serum or liver. The purpose of this study was to determine the median toxic dose (MTD 50 ) for type C botulinum toxin in cattle using an up-down method for toxicologic testing. In addition, the study provided valuable information on the usefulness of the mouse protection bioassay and the type C immunostick ELISA as diagnostic tools in cases of botulism in cattle.
Materials and methods
Experimental design. The MTD 50 for C. botulinum type C toxin was determined using the up-down method for acute toxicity testing as described previously. 2, 3 The starting dose was determined by administering a dose of type C botulinum toxin less than that determined to be toxic in a mouse (1 mouse lethal dose equals 0.1 ng/20-g mouse or 5.0 ng/kg body weight). Subsequently, 7 adult lactating Holstein dairy cows were given C. botulinum type C complex toxin at 0.125 ng/kg (1.25 mouse lethal doses [mlds]/kg), 0.25 ng/kg (2.5 mlds/kg), and 0.50 ng/kg (5.0 mlds/kg).
Each adult lactating Holstein cow, upon arrival, was given a thorough clinical examination to ensure that the animal was in good health and did not have mastitis. None of the animals were pregnant. Animals were housed in a dirt lot with feed and water provided at all times. The body weight in kilograms was determined to calculate the amount of toxin to be administered. Each cow was administered a single dose of toxin. On day 1, C. botulinum type C toxin was administered by intravenous injection into the milk vein. Blood samples were drawn from the milk vein opposite the one used for injection of the toxin just before inoculation (time 0) and 10 min postinoculation (PI) and also at 3, 6, 9, 12, 24, and 48 hr PI. Whole-milk samples were drawn just before inoculation of the toxin (time 0) and at 9, 24, and 48 hr PI.
Each animal was examined at least twice a day for 7 days for clinical signs of botulism (constipation, decreased tail tone, ease of extending the tongue and decreased ability to retract the tongue back into the mouth, decreased palpebral reflex, muscle weakness and muscle fasciculation, paresis, and paralysis). Severe clinical signs were defined as the development of posterior paresis and the inability of the animal to rise and support its weight while standing. Severely affected animals were then euthanized by captive bolt to the head. Cows that did not develop clinical signs were euthanized on day 7 with a captive bolt to the head and necropsied. However, 2 animals that received 0.25 ng/kg of body weight were monitored for an extended period to see if any toxic signs developed after 7 days. Using the up-down procedure for determining MTD 50 , if no positive clinical signs developed during the 7-day period, the next cow was given a higher geometric-level dose as described by the formula Dn ϭ D 1 P (nϪ1) , where D is the dose, n is the subject number, and P is the constant. 2, 3 Once a dose that resulted in botulism (paresis) during the 7-day period was identified, the next test animal was given a lower geometric-level dose. If this animal failed to develop clinical signs of botulism with posterior paresis within the 7-day period, the next higher geometric-level dose was given to the next test animal. This up-down testing was then repeated until 3 reversals were noted between animals having positive clinical signs of botulism and animals that developed no clinical signs of botulism during the 7-day period. The MTD 50 was then determined using the trim-logit method. 2 Toxin. Clostridium botulinum type C complex toxin in a sterile phosphate buffer solution was obtained from a commercial source. a Type C complex toxin was used instead of type C 1 toxin exclusively because in the natural setting the toxin is expressed with both components of the type C toxin present (C 1 and C 2 toxins). Mouse bioassay results provided by the manufacturer allowed standardization of the toxin to 2.5 ϫ 10 3 ng/ ml in phosphate buffer. Aliquots of 6 ml containing 15.0 ϫ 10 3 ng toxin were frozen at Ϫ70 F. After 2 weeks in the Ϫ70 F freezer, an aliquot was thawed, and the mouse lethal dose was determined to be 0.1 ng using standard techniques. 5 Remaining toxin samples were maintained in the Ϫ70 F freezer until use. The amount of toxin administered to the cattle was based on the body weight in kilograms. The toxin was thawed immediately before administration, further diluted to the desired dose in sterile phosphate-buffered saline, and administered intravenously (mammary vein). Thawed samples were used once. Any remaining unused toxin in the 6-ml aliquot was destroyed.
Necropsy and histopathology. Animals were necropsied, and lung, liver, kidney, spleen, rumen, abomasum, ileum, spiral colon, brain, sciatic nerve, and biceps femoris muscle were collected from the euthanized animals for histopathologic examination. Tissues were fixed in 10% neutral buffered formalin, trimmed, embedded in paraffin, sectioned at 7 m, and stained with hematoxylin and eosin.
Evaluation of blood, sera, milk, and liver for the presence of the toxin. Blood (sodium heparin tubes) and serum (red top tubes) samples were collected from each animal at time 0, 10 min PI, and 3, 6, 9, 12, 24, 48, and 72 hr PI. Milk samples were drawn using a portable vacuum milker at 0, 9, 24, and 48 hr, placed into 40-ml aliquots, and frozen immediately at Ϫ70 F. Serum was separated by centrifugation, drawn off, and frozen immediately at Ϫ70 F. Whole-blood (sodium heparin) tubes were refrigerated and shipped on wet ice to the US Geological Survey National Wildlife Health Center, where these and milk samples were tested for type C botulinum toxin using an immunostick ELISA test. 12 Milk, liver, and serum samples were also tested using the mouse protection bioassay 9 for identification of toxin.
Results
Lactating Holstein dairy cows dosed at 0.125 and 0.25 ng/kg remained normal and failed to develop clin- ical signs of botulism during the 7-day observation period ( Table 1 ). The 3 cows given the 0.50-ng/kg dose developed clinical signs of botulism. Three reversals from animals surviving without paresis (0.25 ng/kg) to animals with paresis (0.50 ng/kg) were noted at these doses (Table 1 ; Fig. 1 ) during the 7-day observation period. The MTD 50 for type C botulinum toxin was calculated to be 0.388 ng/kg (3.88 mouse lethal units/kg) using the trim-logit method. 2, 3 Cows administered toxic doses of C. botulinum type C (0.50 ng/kg) did not develop clinical signs of botulism poisoning for the first 48 hours. Between 48 and 56 hours, cows usually became constipated and appeared to strain while defecating. Only small amounts of semidry fecal material were present. Animals elevated their tails while straining to defecate. Between 72 and 96 hours, affected cows became weak and would lie down frequently. Tail tone decreased. Muscle fasciculation of the large-muscle groups of the front and rear legs often began in the affected animals during this time frame (72-96 hours PI). As the animals became weaker, they leaned against the fence or walls of buildings for help in standing. Extracting the tongue from the affected cow's mouth became easier, with slower retraction of the tongue back into the mouth often noted between 72 and 96 hours PI. Weakness progressed to total posterior paresis at 80 hours (cow No. 7), 96 hours (cow No. 3), and 140 hours (cow No. 5) postinjection of the toxin for the 3 animals receiving 0.50 ng/kg of toxin (Table 1) .
At necropsy, all animals that failed to develop clinical signs of botulism appeared normal. The 3 animals that developed clinical signs of botulism (0.50 ng/kg) had markedly dilated rectums that contained abundant dry fecal material. Results of the histologic examination of the tissues mentioned in the Materials and Methods section were normal. Testing whole-blood, serum, liver, and milk samples for the presence of toxin was completed using the immunostick ELISA (heparinized blood and milk) and the mouse protection bioassay (serum, milk, and liver samples). Toxin was not identified in any of the samples collected in this study by either test.
Two of the cows receiving 0.25 ng/kg of toxin that did not develop clinical signs of botulinum intoxication during the 7-day observation period were not euthanized and monitored for a longer period. Some constipation and muscle weakness was observed in 1 animal (cow No. 6) on day 8. This weakness progressed to paresis by day 10. At this time, the animal also showed a marked decrease in tongue retraction and placement and tail tone, and it was euthanized. The other animal (cow No. 4) did not show clinical signs of botulism through 24 months PI.
Discussion
These results demonstrate the sensitivity of cattle to C. botulinum type C toxin. Standardization of the toxin into mouse lethal units reveals that a 0.1-ng dose of toxin is the MTD 50 required to kill a 20-g mouse, which is equivalent to 5.0 ng/kg body weight. Experimental results for the lactating Holstein cows indicate that the MTD 50 for cattle is 0.388 ng/kg. These results demonstrate that the lactating Holstein cow is 12.88 times more sensitive to type C botulinum toxin than a mouse on a per kilogram weight basis. Based on this study, adult lactating dairy cows appear to be very sensitive to type C botulinum toxin and may develop clinical signs of botulism after exposure to low concentrations of toxin. Toxin in the circulation could not be detected by the mouse bioassay at any time point in this study. The mouse bioassay limits testing to the administration of 0.5 ml of serum or any other specimen in a 20-g mouse. This requires that 1 mouse lethal dose be present in the test sample, increasing the difficulty in detecting botulinum toxin in blood, milk, and tissue samples taken from intoxicated animals.
For the botulinum toxin to cause disease, it must be absorbed by the digestive tract and transported to the peripheral nerves by way of the circulatory system. The toxin is a 150-kD protein molecule composed of 2 protein chains, a 100-kD heavy chain and a 50-kD light chain. The heavy chain attaches to receptors on the peripheral nerves, where the entire toxin is incorporated into an endosome in the nerve by pinocytosis. The 50-kD light chain molecule is then released into the cytosol of the nerve. In the cytoplasm, the light chain acts as a zinc-dependent endopeptidase, which cleaves the various docking proteins (syntaxin 1, SNAP-25 [synaptosomal-associated protein of 25 kD], and VAMP [vesicle-associated membrane protein or synaptobrevin-2]) that are required for the release of acetylcholine at the neuromuscular junction and synapses involving the autonomic ganglia, postganglionic parasympathetic nerve endings, and postganglionic sympathetic nerve endings. 7, 9 Consequently, clinical signs usually take several days to develop once the animal is exposed to a toxic dose. An accumulative effect of botulinum toxin is possible because of its incorporation into peripheral nerves and the stability of the light chain in the cytosol. However, from a diagnostic standpoint, the distribution of the toxin into nerves presents an additional challenge because once the toxin is taken up and bound in the cell, it is much less likely to be present in the circulation in appreciable amounts.
Cattle that were administered a toxic dose of botulinum toxin demonstrated mild clinical signs (raising the tail and constipation) of poisoning after 48 hours PI. Major clinical signs (weakness and paresis) were not observed until 72-96 hours PI. Because the clinical signs of botulism are delayed, most of the toxin in the peripheral circulatory system may be already bound to the peripheral nerves and incorporated in the cytosol before one attempts to collect a sample for evaluation.
The 1 cow (cow No. 6) that survived the 7-day observation period after receiving 0.25 ng/kg of toxin developed clinical signs of botulism on day 8, which progressed to paresis on day 10. This animal was affected after the 7-day observation period for acute toxicity studies and was considered as a survivor for determination of the MTD 50 by the up-down method. This demonstrates that the clinical signs of botulism poisoning may not develop until several weeks after exposure to the toxin. In addition, this cow was more sensitive than other Holstein cows that received the same dose of botulinum toxin and did not develop clinical signs. The other cow (cow No. 4) that received 0.25 ng/kg of toxin never developed signs of botulism even after 24 months of observations. These results indicate that survivors that do not develop clinical signs of botulinum intoxication most likely will remain productive animals in the future.
During previous botulism outbreaks on dairies, concern has been raised about the potential for botulinum toxin to be in the milk. The failure to identify botulinum toxin in the milk samples from the cattle challenged with type C botulinum toxin does not prove or disprove that the toxin is present in the milk. However, it does show that the toxin is not concentrated in milk samples to the point of detection by the 2 assays used in the study.
Based on the findings reported in this study, diagnosis of botulism remains presumptive because of the presence of appropriate clinical signs and ruling out other causes of neurologic diseases. Veterinarians must investigate thoroughly suspected cases to rule out the many possible causes of weakness and death in livestock. Efforts to identify toxin in suspected feed sources should also be pursued vigorously. The mouse protection bioassay is useful primarily in cases in which a possible source is identified in the feed or environment. The newly developed specific type C immunostick ELISAs are also useful when type C botulinum toxin is known to occur. Unfortunately, at present, improved diagnostic methods are needed for the detection of botulinum toxin in biological samples from living animals.
